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Introduction
The leading cause of morbidity and mortality during
pregnancy and the puerperium is venous thromboembolism.
Though uncommon, the risk is five times higher in a pregnant
woman than in a non-pregnant woman of similar age.1,2
In pregnancy, all three underlying factors for venous
thrombosis are present: hypercoagulability, venous stasis and
vascular damage (Virchow’s triad).  Of these, the most constant
predisposing factor is increasing venous stasis due to the
pressure of the gravid uterus on the pelvic vasculature.  In
addition the presence of a thrombophilia, (congenital or
acquired) will increase this risk substantially.
During pregnancy hypercoagulability is a physiological
preparation for the haemostatic challenge of delivery.  There
are increases in procoagulant factors, such as von Willebrand
factor, factor VIII, factor V, and fibrinogen together with an
acquired resistance to activated protein C and a reduction in
protein S.  Increases in plasminogen activator inhibitors impair
fibrinolysis.  The third factor of this triad, vascular damage, is a
possible complication of trophoblastic invasion of the uterine
spiral arterioles or of delivery.1,3
Case Report
A 28 year-old female in her second pregnancy, having had
a previous normal full term pregnancy, presented at 34 weeks
gestation with a 7-day history of shortness of breath, initially
on exertion but on presentation also at rest.  The patient had
also been complaining of pleuritic chest pain radiating to her
back. The patient was admitted to the A&E Department.  Arterial
blood gases confirmed arterial hypoxaemia and hypocapnia, and
an ECG (Figure 1) sustained the possibility of pulmonary
thromboembolism.
A diagnosis of pulmonary embolism was made.  The patient
was transferred to the Coronary Care Unit and fully heparinised
(unfractionated heparin), maintaining her APTT between 80 -
100 sec.  Doppler investigation of both lower limbs did not reveal
any venous thrombosis.
A pulmonary perfusion scan was carried out to confirm
diagnosis and assess the severity of the pulmonary embolism.
A low dose of tracer was used due to the pregnancy (37 mmol).
There was almost absent tracer uptake in the left lung field,
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Figure  1: Electrocardiogram on admission showing
a sinus tachycardia (100/min), shortened R-R interval
and a deep S wave in lead I
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Figure 2: Pulmonary perfusion scintigraphy reveals
almost complete absence of perfusion of the left lung
with further segmental defects of uptake in the right lung.
Scan findings are in keeping with extensive
pulmonary embolism
absent uptake in the right upper lobe, and absent uptake in the
lateral basal segment of the right lower lobe.  Extensive bilateral
pulmonary embolism was confirmed (Figure 2).
Because of the severity of the embolus, respiratory function
was not considered adequate for a normal vaginal delivery and
a plan was made for an elective caesarean section at 36 weeks.
Since heparin would have to be stopped at least 6 hours prior to
surgery, a temporary vena-cava filter was inserted.  The
interventional radiologist used a Nitinol® temporary filter taking
into consideration the age of the patient.
The pulmonary-perfusion scan was repeated prior to the
caesarean section and this showed a mild improvement,
although generalised impairment was still present.
Anticardiolipin antibody levels (IgG) were found to be five times
the normal value.  This was highly significant and a diagnosis
of antiphospholipid antibody syndrome was made.
At 36 weeks gestation an elective lower segment caesarean
section was performed in a theatre with facilities for cardio-
pulmonary bypass at hand.
The patient was again fully heparinised after the caesarean
section (Heparin 6500 units/6 hours).  Her general condition
was stable, and the patient was transferred to the High
Dependency Unit.
The temporary filter was removed on 4th December 2001,
the heparin was again stopped 6 hours before.  During the
procedure the extent of the inferior vena cava obstruction was
assessed.  Extensive thrombosis involving the whole of the lower
part of the inferior vena cava prompted the decision to insert a
permanent Nitinol® vena cava filter.  The patient was
warfarinised from the next day and she was discharged a week
later on Warfarin 8mg daily (INR 2-3).
Discussion
Fatal thromboembolism is the leading cause of maternal
mortality in the United Kingdom2 and in most countries in
Europe.  The risks are increased considerably in pregnancy due
to the risk factors outlined above, especially in the presence of
a thrombophilia (estimated to be increased six-fold in Factor V
Leiden mutations).  In pregnancy most cases of deep vein
thrombosis are ileofemoral rather than calf vein thrombosis
(72% vs 9%),3,4 and ileofemoral deep vein thrombosis is more
likely than calf vein thrombosis to lead to pulmonary
thromboembolism.3
Diagnosis depends on a high index of suspicion and
immediate appropriate investigation and treatment.  The
primary diagnostic tool for the diagnosis of pulmonary
embolism in both pregnant and non-pregnant patients is the
ventilation-perfusion scan. 3,5 The reluctance to perform
radiological studies during pregnancy because of concern about
the effects of radiation on fetal development is unjustified, as
the estimated exposure of the fetus to radiation during these
investigations is small, and has not been associated with a
significant risk of fetal injury in studies. 3,6 In this case the clinical
condition of the patient did not correlate with the extent of the
pulmonary compromise; only after the ventilation-perfusion
scan did the extent of the embolism become clear.
Continuous, dose-adjusted, intravenous unfractionated
heparin was used to anticoagulate this patient.  However, most
studies indicate that low-molecular-weight heparin is as
effective and safe as intravenous heparin for the treatment of
acute symptomatic pulmonary embolism.  A number of
advantages such as a simplified therapeutic regimen and
increased bioavailability are evidenced from these
studies. 5,7-10  The use of warfarin in pregnancy is generally
contraindicated.  However it has been advocated for patients
with recurrent pregnancy loss and thromboembolism
associated with the presence of antiphospholipid antibodies.11,12
Anticoagulation therapy should be continued postpartum with
heparin and warfarin; heparin can be discontinued once the
level of anticoagulation with warfarin is adequate.
The use of thrombolytic agents during pregnancy has been
limited to life-threatening situations because of the risk of
maternal bleeding and due to the lack of knowledge of the risk
of placental abruption and fetal death due to these drugs.3,6,13
Although filters in the inferior vena cava have been used
safely and effectively in pregnant women14, carefully designed,
prospective, randomised studies are needed to clearly establish
the safety and utility of vena cava filtration devices. In 1998,
Decousus et al10 published the first and only randomised study
of vena cava filters in the prevention of pulmonary embolism.
They randomised 400 patients with proximal deep vein
thrombosis who were at risk for pulmonary embolism to
receive a vena cava filter or no filter and enoxaparin or
unfractionated heparin.  Four different types of vena cava filters
were used.  Ventilation-perfusion scans were performed at
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baseline and after 8 to 12 days of anticoagulation.  Vena cava
filters were associated with a significant decrease in the
incidence of pulmonary embolism compared with
anticoagulation alone (1.1% versus 4.8%, P=0.03) at 8 to 12 days
after follow-up.  After two years, however, this difference was
not longer statistically significant although the trend still
favoured vena cava filters (3.4% versus 6.3%, P=0.16).
Symptomatic pulmonary embolism occurred at a similar
frequency in both groups after 3 months.  Fatal emboli were
more common in patients treated solely with anticoagulation
(0.5% versus 2.5%).10
In the light of these data, one can conclude that vena cava
filters in combination with standard anticoagulation appear to
offer significantly more protection from pulmonary embolism
than anticoagulation alone.  This additional protection was also
noted in other studies.15,16  However it appears to be short-lived
and does not decrease overall mortality.  In addition, vena cava
filters are associated with a higher incidence of recurrent deep
venous thrombosis over 2 years follow-up.10
Supra-renal placement is recommended in pregnant women
to avoid potential contact between the gravid uterus and the
filter.  This position also provides additional protection against
thromboembolism from pelvic or ovarian veins.15 At follow-up
it is important to ascertain an impairment of renal function due
to the potential obstruction of the suprarenal vena cava. Other
potential complications with vena cava filtration devices are
insertion-site thrombosis, penetration of the inferior vena cava
wall by filter prongs, filter metal fatigue, filter migration and
tilting.15,17
Many investigatiors recommend routine anticoagulation
after vena cava filter placement.10  However little data are
available to support the utility of this practice.  Several case series
have attempted to address this issue.  Although none were able
to demonstrate any benefit of anticoagulation, the retrospective,
unrandomised nature of the studies as well as the limited
duration and intensity of anticoagulation used in some of the
studies suggest that randomised comparisons will be necessary
to resolve the issue.17
50% of thromboembolic events in pregnancy and the
puerperium occur in women with an identifiable thrombophilia.
However, these thrombophilias also occur in 15% of a Western
population.  The thrombophilias comprise a rapidly expanding,
heterogenous group of largely inherited deficiencies of naturally
occurring anticoagulants.  Testing must take into account the
anticoagulation treatment being given to the patient.  A patient
on warfarin can be screened for antithrombin III deficiency,
but not for protein C and S deficiencies.  The opposite holds
true for patients on unfractionated or low molecular weight
heparin.  Molecular analysis (factor II and V) and anticardiolipin
antibodies results are not affected by anticoagulation.  Acquired
thrombophilias due to nephritic syndrome, malignancy and
polycythaemia are rare in pregnancy.6
Conclusions
Acute severe pulmonary venous thromboembolism is an
extremely dangerous complication of what should be a normal
physiological state.  The possibility of a thrombophilia must
always be considered in a pregnant woman if potentially fatal
complications are to be avoided.  Any chance of survival must
rest on a high index of suspicion, prompt appropriate
investigation and aggressive management.
Use of the IVC filter is at present limited but may offer the
protection required to ensure a successful outcome.  More
experience on their use is required, especially with permanent
filters, but we suggest that at least a temporary filter is
mandatory when the patient has been anticoagulated and
delivery is approaching.
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